Skip to main content
logo
Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
15.04
-0.57 (-3.65%)
At close: Mar 13, 2026, 4:00 PM EDT
15.14
+0.10 (0.66%)
After-hours: Mar 13, 2026, 4:45 PM EDT

Nurix Therapeutics Income Statement

Millions USD. Fiscal year is Dec - Nov.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Revenue
83.9854.5576.9938.6329.75
Revenue Growth (YoY)
53.95%-29.14%99.31%29.84%66.95%
Gross Profit
83.9854.5576.9938.6329.75
Selling, General & Admin
52.7445.9442.93831.2
Research & Development
316.9221.63189.15184.5116.43
Total Operating Expenses
369.65267.58232.05222.49147.64
Operating Income
-285.67-213.03-155.06-183.87-117.89
Total Non-Operating Income (Expense)
21.9719.7311.123.510.82
Pretax Income
-263.7-193.3-143.95-180.36-117.06
Provision for Income Taxes
0.760.27--0.13
Net Income
-264.46-193.57-143.95-180.36-117.19
Net Income to Common
-264.46-193.57-143.95-180.36-117.19
Shares Outstanding (Basic)
8767544943
Shares Outstanding (Diluted)
8767544943
Shares Change (YoY)
29.12%23.52%11.79%13.32%173.68%
EPS (Basic)
-3.05-2.88-2.65-3.71-2.73
EPS (Diluted)
-3.05-2.88-2.65-3.71-2.73
Free Cash Flow
-263.47-182.14-89.48-172.05-90.03
Free Cash Flow Per Share
-3.04-2.71-1.65-3.54-2.10
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-340.16%-390.52%-201.41%-476.01%-396.26%
Profit Margin
-314.90%-354.85%-186.98%-466.93%-393.93%
FCF Margin
-313.73%-333.91%-116.23%-445.42%-302.61%
EBITDA
-266.81-196.6-141.41-173.06-111.8
EBITDA Margin
-317.71%-360.41%-183.68%-448.03%-375.81%
EBIT
-285.67-213.03-155.06-183.87-117.89
EBIT Margin
-340.16%-390.52%-201.41%-476.01%-396.26%
Effective Tax Rate
-0.29%-0.14%0.00%0.00%-0.11%
Updated Nov 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q